San Diego-centered Viking Therapeutics marked alone as a serious competitor during the weight loss drug market place in February right after revealing promising data from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the company